Ultrastructural properties of bone mineral of control and tiludronate-treated osteoporotic rat

被引:23
作者
Rohanizadeh, R
LeGeros, RZ
Bohic, S
Pilet, P
Barbier, A
Daculsi, G
机构
[1] NYU, Coll Dent, Calcium Phosphate Res Lab, New York, NY 10010 USA
[2] Ctr Rech INSERM 99 03 Mat Interet Biol, Nantes, France
[3] Sanofi Res Dept, Montpellier, France
关键词
tiludronate; osteoporosis; ovariectomy; bone mineralization; high resolution TEM; ultrastructural characterization;
D O I
10.1007/s002230001141
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bisphosphonates have been widely used in the treatment of human bone pathologies including osteoporosis. In this case, bisphosphonates have been shown to reduce bone resorption, thereby increasing the mass and mechanical resistance of bone. Determining the effects of these molecules on the properties of the bone apatite crystals could provide a better insight into the mechanism of bisphosphonate/bone interaction. The aim of this study was to determine the ultrastructural effects of a third generation bisphosphonate (tiludronate) on the morphology, size, distribution, chemical composition, and structure of apatite crystals in bone (trabecular) in a rat osteoporotic model. Four groups of rats were studied: (1) sham operated, (2) untreated ovariectomized (OVX), (3) OVX rats which received 35 mg/kg of tiludronate, (4) OVX rats which received 160 mg/kg of tiludronate. The rats of groups 3 and 4 received tiludronate orally in 2 consecutive days every week for I year. Scanning electron microscopy (SEM), high and low resolution transmission electron microscopy (TEM), and electron microprobe analysis (EDX) were used for the ultrastructural characterization of the bone mineral. This study demonstrated that tiludronate slightly increased the width of bone apatite crystals without changing any other crystal characteristics.
引用
收藏
页码:330 / 336
页数:7
相关论文
共 58 条
[1]  
AMMANN P, 1993, J BONE MINER RES, V8, P1491
[2]  
BARBIER A, 1990, 3 INT S OST HAND AAL, P1119
[3]  
BARBIER A, 1991, J BONE MINER RES S, V6, pS217
[4]   Bisphosphonates in the treatment of osteoporosis [J].
Bell, NH ;
Johnson, RH .
ENDOCRINE, 1997, 6 (02) :203-206
[5]   Determining mineral content variations in bone using backscattered electron imaging [J].
Bloebaum, RD ;
Skedros, JG ;
Vajda, EG ;
Bachus, KN ;
Constantz, BR .
BONE, 1997, 20 (05) :485-490
[6]   TILUDRONATE - BONE PHARMACOLOGY AND SAFETY [J].
BONJOUR, JP ;
AMMANN, P ;
BARBIER, A ;
CAVERZASIO, J ;
RIZZOLI, R .
BONE, 1995, 17 (05) :S473-S477
[7]  
Boyde A, 1996, MICROSC RES TECHNIQ, V33, P92
[8]   Long-term effects of bisphosphonates on the growing skeleton - Studies of young patients with severe osteoporosis [J].
Brumsen, C ;
Hamdy, NAT ;
Papapoulos, SE .
MEDICINE, 1997, 76 (04) :266-283
[9]   BISPHOSPHONATES DIRECTLY INHIBIT THE BONE-RESORPTION ACTIVITY OF ISOLATED AVIAN OSTEOCLASTS INVITRO [J].
CARANO, A ;
TEITELBAUM, SL ;
KONSEK, JD ;
SCHLESINGER, PH ;
BLAIR, HC .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (02) :456-461
[10]  
Chestnut Charles H. Iii, 1995, P391